TransMedics Group, Inc. (NASDAQ:TMDX) CFO Stephen Gordon Sells 2,060 Shares

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) CFO Stephen Gordon sold 2,060 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $135.93, for a total transaction of $280,015.80. Following the transaction, the chief financial officer now directly owns 21,299 shares in the company, valued at approximately $2,895,173.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Stephen Gordon also recently made the following trade(s):

  • On Wednesday, May 29th, Stephen Gordon sold 20,000 shares of TransMedics Group stock. The stock was sold at an average price of $141.40, for a total transaction of $2,828,000.00.
  • On Monday, May 6th, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $128.00, for a total transaction of $1,920,000.00.
  • On Monday, April 1st, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00.
  • On Friday, March 8th, Stephen Gordon sold 1,903 shares of TransMedics Group stock. The stock was sold at an average price of $87.63, for a total value of $166,759.89.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded up $0.61 on Wednesday, hitting $135.09. The stock had a trading volume of 782,644 shares, compared to its average volume of 769,708. The firm’s 50 day moving average price is $110.02 and its 200-day moving average price is $90.69. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $144.23. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of -402.94 and a beta of 1.95.

TransMedics Group (NASDAQ:TMDXGet Free Report) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The firm’s quarterly revenue was up 132.9% on a year-over-year basis. During the same period last year, the firm posted ($0.08) EPS. On average, equities research analysts predict that TransMedics Group, Inc. will post 0.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TMDX shares. Stephens began coverage on TransMedics Group in a research note on Tuesday. They issued an “overweight” rating and a $151.00 price objective on the stock. TD Cowen upped their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Piper Sandler reiterated an “overweight” rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. Morgan Stanley boosted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Finally, Oppenheimer raised their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.57.

View Our Latest Report on TMDX

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Venturi Wealth Management LLC acquired a new stake in TransMedics Group during the 1st quarter valued at $30,000. Fidelis Capital Partners LLC bought a new stake in shares of TransMedics Group during the first quarter worth $35,000. Cutler Group LLC CA increased its stake in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after buying an additional 600 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after buying an additional 222 shares during the last quarter. Finally, RiverPark Advisors LLC raised its holdings in shares of TransMedics Group by 19.5% in the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after buying an additional 215 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

See Also

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.